Key opinion leader Benjamin Garmezy, MD, discusses the shifting landscape of prostate cancer management, the importance of identifying lethal cases, and the challenges in risk stratification and prognosis.
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen